At first glance, 2015 looks like the year the London Stock Exchange turned its back on biotech once again. Acacia Pharma and Shield Therapeutics both tried and failed to be 2015's Circassia, the big success story of 2014, leaving AIM listings and outliers such as PureTech as the most notable London IPOs of the year. And yet, from another angle, 2015 looks like a landmark year.
Now that Gilead faces increased competition for its goliath share of the U.S. hep C market with Merck's fresh arrival on the scene, the Big Biotech is keeping a mental checklist of potential new collaborations and acquisitions that might help rev up some added excitement for the company's shares.
LAM Therapeutics, a biotech co-founded by Yale University entrepreneur Jonathan Rothberg, raised $40 million to fund its work on an early-stage pipeline of treatments for rare diseases and cancer.
After more than 60 days without a single successful biotech IPO, a pair of drug developers have made their way to the Nasdaq, going public without offering discounts and heralding hope that a dismal market might pick back up.
The new French biotech Enyo Pharma has raised a good chunk of money in its first round of financing as it looks to start human testing for a potential hepatitis B cure.
Whatever Takeda learned about Cambridge, MA-based Mersana Therapeutics over the course of its two-year collaboration, the experience left them eager for much, much more. The biotech announced today that the Japanese pharma company snagged ex-U.S. commercial rights to its lead preclinical antibody drug conjugate while expanding the realm of their partnership to include a range of new targets.
Kadmon, a biotech founded by once-jailed ImClone CEO Sam Waksal, is gearing up to test the waters for an IPO, according to CNBC, braving a brutal climate for drug developers on Wall Street after at least two previous efforts to go public amounted to nothing.
NewLink Genetics, which partnered with Merck on a promising Ebola program, has joined the incipient race to find a vaccine that can be used to combat the recent spread of the Zika virus.
Two prominent women in the biotech community were so appalled by reports about a party at J.P. Morgan featuring scantily clad models that they've written an open letter to the biotech industry as a "shot across the bow" designed to end such festivities once and for all.
GlaxoSmithKline, working with Adaptimmune on therapies that use the body's machinery to fight cancer, is sweetening the deal for its partner, promising more cash to accelerate development of a promising treatment for soft tissue sarcoma.
Cambridge, U.K.'s Mission Therapeutics raised £60 million ($86 million) in equity to fund its work in a novel biological pathway, uniting high-profile investors Imperial Innovations and Woodford Patient Capital Trust in the round.
Pfizer has quietly shuttered a Phase II Alzheimer's drug study, noting the termination in a pipeline update released today with its annual numbers for 2015. And shares of Axovant tumbled 16% on the news as it faces fresh questions about the implications of the failure on a similar drug it has pushed into a Phase III trial.
Following up on a plan to slim operations and cut $1.6 billion in costs, the new CEO at Paris-based Sanofi is taking an ax to 500 jobs, according to press reports.
Eight months after wrapping its first venture round with a $30 million bankroll, Cambridge, MA-based Spero Therapeutics has gone back to the well for $30 million more.
The biotech team at Index Ventures is splitting away to focus exclusively on what they do best: jump-starting new therapeutic programs in Europe.
A pair of early-stage biotech companies has joined the thinning queue of drug developers trying to go public amid a painful market correction, angling to raise more than $135 million combined as the industry sputters.
About the best that can be said for biotech stocks right now is that a punishing January is finally over. Unless, of course, you have some sort of vaccine or new technology that just might be used one day to combat the sudden onslaught of the Zika virus.
Bristol-Myers Squibb, Pfizer and Eisai are targeting Japan's growing pharma market with a pair of deals in the cardiovascular and oncology spaces, signing back-loaded agreements to push new drugs in the country.
A new therapeutic model for T-cell engineering promises to make it a more precise weapon that can tackle solid tumors while avoiding off-target reactions that threaten patients.
Canada's Transition Therapeutics is touting positive Phase II data for a once-a-week GLP-1 treatment, triggering a decision point for partner Eli Lilly, which bought into the program in a $247 million deal.